RankAlpha logo
Back to Rankings

SNDX

SyndaxB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
View Chart
Current thesis
The bull case is that SNDX has crossed from story stock to commercial oncology company: two approved products generated more than $275M of 2025 product sales, sequential launch growth remained strong into 4Q25, and management is signaling a path to profitability if operating expenses stay stable [#8-K-2026-02-26].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.7.
What can break
Frontline AML studies for revumenib take longer, enroll slower, or produce weaker-than-expected efficacy or safety.
Momentum
67
Value
41
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $29.00 · Bull $36.00 · Bear $16.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $39.45
Why
Momentum67 · Δ7d +30.7
Value41 · Δ7d -0.0
Sentiment73 · Δ7d +6.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
67
26% active weight
Current posture
7d trendFlat
Δ7d
+30.7
Δ21d
+53.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
73
34% active weight
Current posture
7d trendImproving
Δ7d
+6.7
Δ21d
-5.7
Why this grade

Composite grade B. Momentum 67.0 / Value 41.1 / Sentiment 72.8

Fundamentals (TTM)
As of 2026-07-22
Market Cap
$1.95B
Beta
0.46
Shares Out
88.61M
P/E (TTM) · Derived
-6.7
P/S (TTM)
15.75
P/FCF (TTM) · Derived
-6.89
Rev YoY
+223.6%
EPS YoY
-50.9%
Gross Margin
+96.0%
Op Margin
-275.1%
Net Debt
-$48.64M
Current Ratio
5.47
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology